Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VX 210

Drug Profile

VX 210

Alternative Names: BA-210; Cethrin; VX-210

Latest Information Update: 05 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAxone Therapeutic
  • Developer BioAxone Biosciences; Vertex Pharmaceuticals
  • Class Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action Rho GTP-binding protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Glaucoma; Optic nerve disorders; Spinal cord injuries

Most Recent Events

  • 24 Oct 2018 Discontinued - Phase-II for Spinal cord injuries in Canada (Epidural)
  • 24 Oct 2018 Discontinued - Phase-II/III for Spinal cord injuries (In adolescents, In adults) in USA (Epidural)
  • 24 Oct 2018 Discontinued - Preclinical for Age-related macular degeneration in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top